[O32] 神経筋疾患 3

[O32-1] SUNFISH：脊髄性筋萎縮症（SMA）II型及びIII型患者におけるリスジプラム４8ヶ月継続投与時の有効性及び安全性

^○齋藤 加代子¹, 加藤 環¹, John W Day², Nicolas Deconinck³, Elena S Mazzone⁴, Andres Nascimento⁵, Maryam Oskoui⁶, Carole Vuillerot⁷, Giovanni Baranello⁸, Laurent Servais⁹, Jessica Braid¹⁰, Marianne Gerber¹⁰, Carmen Martin¹⁰, Wai Yin Yeung¹⁰, Eugenio Mercuri⁴ (1.東京女子医科大学ゲノム診療科, 2.Department of Neurology, Stanford University, Palo Alto, CA, USA, 3.Neuromuscular Reference Center, UZ Gent, Ghent, Belgium, 4.Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy, 5.Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Deu, Fundacion Sant Joan de Deu, CIBERER - ISC III, Barcelona, Spain, 6.Departments of Pediatrics and Neurology Neurosurgery, McGill University, Montreal, Canada, 7.Department of Pediatric Physical Medicine and Rehabilitation, Hopital Mere Enfant, CHU-Lyon, Bron, France, 8.Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health University College London, London, UK, 9.MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, United Kingdom, 10.F. Hoffmann-La Roche Ltd., Basel, Switzerland)